ArticleCardiology research2025
Epidemiology and Short-Term Outcomes of Heart Failure With Preserved and Mildly Reduced Ejection Fraction in Colombia: Insights of the Colombian Heart Failure Registry (RECOLFACA).
Article in Cardiology research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Cardio-Oncologic Considerations in Heart Failure With Mildly Reduced Ejection Fraction: Prevalence and Prognostic Impact of Malignancies.Journal of the American Heart Association · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Heart failure with preserved or mildly reduced ejection fraction (HFpEF/HFmrEF) has differences in therapy and development when compared with HF with reduced EF (HFrEF). We aimed to describe the clinical characteristics and all-cause mortality of patients with HFpEF/HFmrEF compared to those with HFrEF from the Colombian Heart Failure Registry (RECOLFACA). Methods: RECOLFACA included Colombian adult patients with ambulatory HF recruited from 2017 to 2019. All-cause mortality was our main outcome. We used the Kaplan-Meier method, life table, and Cox proportional hazard models to evaluate the role of the comorbidities on mortality, with a significant P-value of < 0.05. All statistical tests were two-tailed. Results: We included 2,514 patients, and 1,139 (45.3%) had a diagnosis of HFpEF or HFmrEF. HFpEF/HFmrEF diagnosis was not significantly related to either higher or lower risk of mortality compared to an HFrEF diagnosis; however, the individual risk factors for this outcome varied between the two groups. Health-related quality of life (HRQL) was a common risk factor for both groups. Conclusion: Although the EF classification was not a significant risk factor for mortality, patients with HFpEF/HFmrEF exhibited a unique profile of risk factors for mortality, the HRQL, highlighting the relevance of an adequate classification of the HF patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.